Vascular healing in high-bleeding-risk patients at 3-month after everolimus-eluting stent versus biolimus A9-coated stent implantation: insights from analysis of optical coherence tomography and coronary angioscopy

被引:0
作者
Hiroshi Koiwaya
Kensaku Nishihira
Kosuke Kadooka
Nehiro Kuriyama
Yoshisato Shibata
机构
[1] Miyazaki Medical Association Hospital,Cardiovascular Center
[2] 1173 Arita,undefined
来源
Cardiovascular Intervention and Therapeutics | 2023年 / 38卷
关键词
Drug-eluting stent; Drug-coated stent; High bleeding risk; Optical coherence tomography; Angioscopy;
D O I
暂无
中图分类号
学科分类号
摘要
The prevalence of high-bleeding-risk (HBR) patients who undergo coronary stenting has been reported as 20–40%. This study sought to assess vascular healing in HBR patients by coronary angioscopy (CAS) and optical coherence tomography (OCT). We prospectively analyzed 38 HBR patients with coronary artery disease who successfully underwent everolimus-eluting stent (EES) implantation (20 patients, 23 lesions) or drug-coated stent (DCS) implantation (18 patients, 18 lesions). Follow-up coronary angiography, CAS, and OCT were planned at 3 months after the procedure. The clinical characteristics and inclusion criteria of HBR were comparable between groups. CAS analysis showed that mean yellow color grade was significantly higher with EES than with DCS (1.33 [1.0, 1.67] vs. 1.0 [0.67, 1.5]; P = 0.04). In contrast, OCT analysis demonstrated that most struts in both groups were well-apposed struts with neointimal coverage (93.9% each; P = 1.00), and percentages of the mean neointimal area were comparable between EES and DCS (4.4 ± 3.5 mm2 vs. 4.5 ± 4.1 mm2; P = 0.91). The frequency of uncovered struts was significantly lower with EES than with DCS (2.4% vs. 5.3%; P < 0.001), whereas the frequency of malapposed struts was significantly higher with EES than with DCS (3.5% vs. 0.8%; P < 0.001). During follow-up, no stent thrombosis or major bleeding complications were encountered in either group. Among HBR patients, both EES and DCS demonstrated good vascular healing at 3-month follow-up with some different features in CAS and OCT assessments.
引用
收藏
页码:64 / 74
页数:10
相关论文
共 190 条
  • [1] Leon MB(1998)A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators N Engl J Med 339 1665-1671
  • [2] Baim DS(2009)Gastrointestinal bleeding in patients with acute coronary syndromes: Incidence, predictors, and clinical implications J Am Coll Cardiol 54 1293-1302
  • [3] Popma JJ(2018)Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores J Am Heart Assoc 7 e008708-260
  • [4] Gordon PC(2018)2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS Eur Heart J 39 213-1196
  • [5] Cutlip DE(2019)JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome Circ J 83 1085-1274
  • [6] Ho KK(2013)Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18334 patients J Am Coll Cardiol Intv 6 1267-209
  • [7] Nikolsky E(2016)One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: Short and optimal duration of dual antiplatelet therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Cardiovasc Interv Ther 31 196-2047
  • [8] Stone GW(2015)Polymer-free drug-coated coronary stents in patients at high bleeding risk N Engl J Med 373 2038-2747
  • [9] Kirtane AJ(2011)Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2736-116
  • [10] George SM(2020)Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics Cardiovasc Interv Ther 35 105-346